A targeted psychological treatment for sleep problems in young people at ultra-high risk of psychosis in England (SleepWell): a parallel group, single-blind, randomised controlled feasibility trial
Open accessThe DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Sleep disturbance is common and problematic for young people at ultra-high risk of psychosis. Sleep disruption is a contributory causal factor in the occurrence of mental health problems, including psychotic experiences, anxiety, and depression. The implication is that treating sleep problems might have additional benefits on mental health outcomes in individuals at high risk. The present study had two aims: first, to establish the feasibility and acceptability of a randomised controlled trial to treat sleep problems with the aim of reducing psychotic experiences in young people at ultra-high risk of psychosis; and second, to provide proof of concept of the clinical efficacy of the treatment. METHODS: We did a parallel group, single-blind, randomised controlled feasibility trial in two National Health Service trusts in England. Eligible participants were aged 14-25 years, a patient of mental health services, assessed as being at ultra-high risk of psychosis on the Comprehensive Assessment of At-Risk Mental States, and having current sleep problems (score of ≥15 on the self-report Insomnia Severity Index [ISI]). Participants were randomly assigned (1:1) to either a targeted psychological therapy for sleep problems (SleepWell) plus usual care or usual care alone via an automated online system, with non-deterministic minimisation that balanced participants for ISI score and referring service. The SleepWell therapy was delivered on an individual basis in approximately eight 1-h sessions over 12 weeks. Assessments were done at 0, 3, and 9 months, with trial assessors masked to treatment allocation. The key feasibility outcomes were the numbers of patients identified, recruited, and retained, treatment uptake, and data completion. Treatment acceptability was measured with the Abbreviated Acceptability Rating Profile (AARP). In preliminary clinical assessments, the primary clinical outcome was insomnia at 3 and 9 months assessed with the ISI, reported by randomised group (intention-to-treat analysis). Safety was assessed in all randomly assigned participants. The trial was prospectively registered on ISRCTN, 85601537, and is completed. FINDINGS: From Nov 18, 2020, to Jan 26, 2022, 67 young people were screened, of whom 40 (60%) at ultra-high risk of psychosis were recruited. Mean age was 16·9 years (SD 2·5; range 14-23), and most participants identified as female (n=19 [48%]) or male (n=19 [48%]) and as White (n=32 [80%]). 21 participants were randomly assigned to SleepWell therapy plus usual care and 19 to usual care alone. All participants provided data on at least one follow-up visit. 39 (98%) of 40 participants completed the primary outcome assessment at 3 and 9 months. 20 (95%) of 21 participants assigned to SleepWell therapy received the prespecified minimum treatment dose of at least four sessions. The median treatment acceptability score on the AARP was 48 (IQR 46 to 48; n=17; maximum possible score 48). At the post-intervention follow-up (3 months), compared with the usual care alone group, the SleepWell therapy group had a reduction in insomnia severity (ISI adjusted mean difference -8·12 [95% CI -11·60 to -4·63]; Cohen's d=-2·67 [95% CI -3·81 to -1·52]), which was sustained at 9 months (ISI adjusted mean difference -5·83 [-9·31 to -2·35]; Cohen's d=-1·91 [-3·06 to -0·77]). Among the 40 participants, eight adverse events were reported in six participants (two [11%] participants in the usual care group and four [19%] participants in the SleepWell therapy group). One serious adverse event involving hospital admission for a physical health problem was reported in the SleepWell therapy group, and one patient in the usual care alone group transitioned to psychosis. None of these events were classed as being related to trial treatment or procedures. INTERPRETATION: A randomised controlled trial of a targeted psychological sleep therapy for young people at ultra-high risk of psychosis is feasible. Patients can be retained in the trial and assessments done by masked assessors. Uptake of the sleep therapy was high, and we found preliminary evidence of sustained reductions in sleep problems. A definitive multicentre trial is now needed. FUNDING: NIHR Research for Patient Benefit and NIHR Oxford Health Biomedical Research Centre.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“only two studies reported using all six blinding methods identified in the content analysis [52, 69].”
From Blinding outcome assessors in randomised controlled trials of psychological interventions: how is it done? A narrative review (2026) · cites this paper as [69]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies that provided extensive detail about all blinding methods strengthen confidence in the validity of findings [52, 69].”
From Blinding outcome assessors in randomised controlled trials of psychological interventions: how is it done? A narrative review (2026) · cites this paper as [69]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Another excellent example by Waite et al. described specific details such as considerations around room bookings [69].”
From Blinding outcome assessors in randomised controlled trials of psychological interventions: how is it done? A narrative review (2026) · cites this paper as [69]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“It may be preferable to base blinding efficacy estimates on outcome assessors’ reports of whether they have been unblinded, rather than their guesses, as was done in a number of studies [36, 40, 56, 60, 69].”
From Blinding outcome assessors in randomised controlled trials of psychological interventions: how is it done? A narrative review (2026) · cites this paper as [69]
The cited source says what the claim attributes to it.
In the citing paper
“Sleep dysfunction is treatable in clinical populations experiencing hallucinations.”
From Towards an Integrative Account of Potential Mechanisms Mediating the Path From Sleep Dysfunction to Hallucinations (2025) · cites this paper as [113]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Power Analysis for the Behavioral Sciences
Muller, K. (1989) · Technometrics · doi:10.1080/00401706.1989.10488618 · Cited by 99,167
Lovibond, P. F., & Lovibond, S. H. (1995) · Behaviour Research and Therapy · doi:10.1016/0005-7967(94)00075-u · Cited by 14,523
Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)
Herdman, M., Gudex, C., Lloyd, A., Janssen, M., Kind, P., Parkin, D., Bonsel, G., & Badia, X. (2011) · Quality of Life Research · doi:10.1007/s11136-011-9903-x · Cited by 9,795
Cohen, J. (1992) · Psychological Bulletin · doi:10.1037//0033-2909.112.1.155 · Cited by 8,771
Validation of the Insomnia Severity Index as an outcome measure for insomnia research
Bastien, C. (2001) · Sleep Medicine · doi:10.1016/s1389-9457(00)00065-4 · Cited by 8,067
Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157
Network analysis: An integrative approach to the structure of psychopathology
Borsboom, D., & Cramer, A. O. J. (2013) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-050212-185608 · Cited by 4,359
Two-Process Model of Sleep Regulation
(2009) · Encyclopedia of Neuroscience · doi:10.1007/978-3-540-29678-2_6166 · Cited by 3,899
The PHQ-15: Validity of a New Measure for Evaluating the Severity of Somatic Symptoms
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2002) · Psychosomatic Medicine · doi:10.1097/00006842-200203000-00008 · Cited by 3,298
Sample size of 12 per group rule of thumb for a pilot study
Julious, S. A. (2005) · Pharmaceutical Statistics · doi:10.1002/pst.185 · Cited by 3,068
Research works printed but not linked: 1
- Waite, 2020, Chapter 20—Better sleep: evidence-based interventions, 465
Cited by
Minichino, A., Davies, C., Karpenko, O., Christodoulou, G. N., Ramalho, R., Nandha, S., Damiani, S., Provenzani, U., Esposito, C. M., Mensi, M. M., et al. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-02902-8 · Cited by 54
“The meta-analytic estimates on acceptability of preventative interventions in CHR-P did not show any signi fi cant difference for any of the active interventions when compared to the respective control interventions.”
InfluentialPalagini, L., Aquino, G., Alfì, G., Massoni, L., Gambini, M., Miniati, M., Marazziti, D., Riemann, D. W., Gemignani, A., & Geoffroy, P. A. (2024) · Sleep Medicine · doi:10.1016/j.sleep.2024.10.033 · Cited by 42
Sleep and circadian difficulties in schizophrenia: presentations, understanding, and treatment
Freeman, D., & Waite, F. (2025) · Psychological Medicine · doi:10.1017/s0033291725000297 · Cited by 14
“For example, in the SleepWell trial, 40 patients at ultra-high risk of psychosis were randomized to receive sleep therapy plus usual care or usual care alone (Waite et al., 2023).”
Self-citationFormica, M., Fuller‐Tyszkiewicz, M., Reininghaus, U., Kempton, M. J., Delespaul, P., de Haan, L., Nelson, B., Mikocka‐Walus, A. A., OLIVE, L. S., Ruhrmann, S., et al. (2024) · Psychological Medicine · doi:10.1017/s0033291724000400 · Cited by 14
“…been supported in those meeting insomnia criteria in the CHR population, with a case-series (Bradley et al., 2018) and a recent RCT of 40 participants (Waite et al., 2023) showing preliminary support for up to a 9-month symptomatic improvement following the reception of tailored sleep intervention.”
BackgroundInfluentialLunsford‐Avery, J. R., Falls, A., Cary, S., & Duke, N. N. (2024) · Current Sleep Medicine Reports · doi:10.1007/s40675-024-00300-0 · Cited by 13
Metadata
- Authors
- Waite, F., Černis, E., Kabir, T., Iredale, E., Johns, L., Maughan, D., Diamond, R., Seddon, R., Williams, N., Yu, L.-M., & Freeman, D.
- Affiliations
- Oxford Health NHS Foundation Trust (GB)
- McPin Foundation (GB)
- University of Oxford (GB)
- Corresponding author
- Waite, Felicity
- ORCID
- Venue
- The Lancet Psychiatry
- Publisher
- Elsevier BV
- Published
- 2023-09
- Volume
- 10
- Issue
- 9
- Pages
- 706-718
- ISSN
- 2215-0366 (ISSN-L)
- OpenAlex
- W4385623173
- Cited by
- 37
- References
- 55
- Citations by year
- 2026: 17 · 2025: 11 · 2024: 7 · 2023: 2
- FWCI
- 8.94
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- The Lancet Psychiatry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (publishedVersion, cc-by)
- Funders
- Wellcome Trust (102176/B/13/Z)
- National Institute for Health and Care Research
- National Institute for Health Research Research for Patient Benefit (NIHR200481)
- NIHR Oxford Biomedical Research Centre (BRC-1215–2000, NIHR203316)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Keywords
- sleep disorders, insomnia, youth, psychosis prevention, psychotic experiences, treatment acceptability, feasibility, Insomnia Severity Index, mental health services, treatment safety, clinical high risk for psychosis, anxiety, recruitment and retention
- MeSH terms
- Adolescent, Cost-Benefit Analysis, England, Feasibility Studies, Female, Humans, Sleep Initiation and Maintenance Disorders, Male, Psychotic Disorders, Sleep Wake Disorders, State Medicine, Cognitive Behavioral Therapy, Single-Blind Method, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A targeted psychological treatment for sleep problems in young people at ultra-high risk of psychosis in England (SleepWell): a parallel group, single-blind, randomised controlled feasibility trial. https://app.cochat.ai/papers/10.1016/s2215-0366(23)00203-1
- The paper
- Waite, F., Černis, E., Kabir, T., Iredale, E., Johns, L., Maughan, D., Diamond, R., Seddon, R., Williams, N., Yu, L.-M., & Freeman, D. (2023). A targeted psychological treatment for sleep problems in young people at ultra-high risk of psychosis in England (SleepWell): a parallel group, single-blind, randomised controlled feasibility trial. The Lancet Psychiatry. https://doi.org/10.1016/s2215-0366(23)00203-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

